Aktis Oncology director sells 4,856 shares after exercise
Aktis Oncology director Ken Herrmann exercised vested stock options and sold the resulting shares on July 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aktis Oncology director Ken Herrmann exercised vested stock options and sold the resulting shares on July 20, 2026. He exercised options for 3,506 shares at $0.08 per share and 1,350 shares at $1.91 per share, acquiring 4,856 common shares. He then sold 4,856 common shares at a weighted average price of $24.5622 per share in transactions priced between $24.50 and $24.66.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 3,506 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F2 | 1,350 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,506 | $0.08 | $280.48 |
| Exercise | Common Stock | 1,350 | $1.91 | $3K |
| Sale | Common Stock F1 | 3,506 | $24.5622 | $86K |
| Sale | Common Stock F1 | 1,350 | $24.5622 | $33K |
Footnotes (2)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2. These options have vested in full.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
weighted average price financial
derivative security financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did Ken Herrmann report for Aktis Oncology (AKTS)?
What stock options did Herrmann exercise in this AKTS insider transaction?
Were the Aktis Oncology (AKTS) stock options fully vested when exercised?
Was Herrmann’s AKTS trade under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.